


DPR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of

Daniel Achard, et al

Examiner: Deepak R. Rao

Application No.:

10/771,764

Art Unit: 1624

Filed:

February 4, 2004

Title: **Pharmaceutical Compositions Containing 3-Aminoazetidine Derivatives, Novel Derivatives and Their Preparation**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

April 26, 2006

Date of Deposit

Brian Pritchett

Brian Pritchett

Signature

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98


Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination under §1.114 whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

- (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



Irving Newman, Reg. No. 22,638
Attorney/Agent for Applicant

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2785
Telefax (908) 231-2626
sanofi-aventis Docket No. ST00008 US CNT1



Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|------------------------|
| Substitute for form 1449B/PTO | | <i>Complete if Known</i> | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | |
| (use as many sheets as necessary) | | | |
| Sheet | 1 | of | 1 |
| | | Application Number | 10/771,764 |
| | | Filing Date | 02-04-2004 |
| | | First Named Inventor | ACHARD, et. al. |
| | | Group Art Unit | 1624 |
| | | Examiner Name | Deepak R. Rao |
| | | Attorney Docket Number | ST00008 - US - CNT - 1 |

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| | | MANEUF, Y.P., et. al., Cannabinoid Receptor-Mediated Modulation of Gabaergic Transmission in the Basal Ganglia Implications for the Treatment of Parkinson's Disease?, The Basal Ganglia V, Plenum Press, New York, Vol. 21, (1996) pp. 183 - 189 | |
| | | MANEUF, Y.P., et. al., The Cannabinoid Receptor Agonist WIN 55,212-2 Reduces D2, but not D1, Dopamine Receptor-Mediated Alleviation of Akinesia in the Reserpine-Treated Rat Model of Parkinson's Disease, Experimental Neurology Vol. 148, pp. 265-270 (1997) | |
| | | PERTWEE, R.G., et. al., Neuropharmacology and Therapeutic Potential of Cannabinoids, Addiction Biology (2000) Vol. 5, pp 37-46 | |
| | | PUFFENBARGER, R.A., et. al., Molecular Biology of the Enzymes that Degrade Endocannabinoids, Current Drug Targets - CNS & Neurological Disorders - (2005) Vol. 4, pp. 625-631 | |
| | | WESTLAKE, W.M., et. al., Cannabinoid Receptor Binding and Messenger RNA Expression in Human Brain: An Invitro Receptor Autoradiography and In Situ Hybridization Histochemistry Study of Normal Aged and Alzheimer's Brains, Neuroscience Vol. 63, No. 3, pp. 637-652 (1994) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Daniel Achard, et al

Application No.: **10/771,764**

Filed: **February 4, 2004**

Title: **Pharmaceutical Compositions Containing 3-Aminoazetidine Derivatives, Novel Derivatives and Their Preparation**

Examiner: **Deepak R. Rao**

Art Unit: **1624**

Certificate of Mailing or Transmission
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.
Date of Deposit Apr. 1 26, 2006
Printed Name of Person Signing Certificate Brian Pritchett

Signature


**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. **18-1982** in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

Respectfully submitted,


Irving Newman, Reg. No. 22,638
Attorney/Agent for Applicant

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-2785
Telefax (908) 231-2626

sanofi-aventis Docket No. ST00008 US CNT1